ADOC regimen: (doxorubicin, cisplatin, vincristine, cyclophosphamide 92% response rate (34 of 37 patients), including complete responses in 43% PAC regimen: cisplatin, doxorubicin, cyclophosphamide 50% response rate, including 3 complete responses. Fornasiero A, Daniele O, Ghiotto C, et al.: Chemotherapy for invasive thymoma: a 13-year experience. Cancer 68(1): 30-33, 1991.
|